XML 45 R29.htm IDEA: XBRL DOCUMENT
v3.26.1

Income and expenses | 12 Months Ended
--- | ---
Dec. 31, 2025
Income and expenses |
Income and expenses | 22 Income and expenses 22.1 Revenue 22.1.1 Disaggregated revenue information ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the year ended December 31, 2025
​ | ​ ​ ​ | Materialise | ​ ​ ​ | Materialise | ​ ​ ​ | Materialise | ​ ​ ​ | Total | ​ ​ ​ | ​ | ​ ​ ​ | ​
in 000€ | ​ | Medical | ​ | Software | ​ | Manufacturing | ​ | segments | ​ | Unallocated | ​ | Consolidated
Geographical markets |  | ​ |  | ​ |  | ​ |  | ​ |  | ​ |  | ​
United States of America (USA) |  | 77,990 | ​ | 14,929 | ​ | 17,967 | ​ | 110,886 | ​ | — | ​ | 110,886
Americas other than USA |  | 5,451 | ​ | 571 | ​ | 223 | ​ | 6,245 | ​ | — | ​ | 6,245
Europe (without Belgium) & Africa |  | 41,412 | ​ | 16,372 | ​ | 67,229 | ​ | 125,013 | ​ | — | ​ | 125,013
Belgium |  | 1,727 | ​ | 164 | ​ | 4,265 | ​ | 6,156 | ​ | — | ​ | 6,156
Asia Pacific |  | 7,658 | ​ | 8,871 | ​ | 2,803 | ​ | 19,332 | ​ | — | ​ | 19,332
Total revenue from contracts with customers |  | 134,239 | ​ | 40,907 | ​ | 92,486 | ​ | 267,633 | ​ | — | ​ | 267,633
Type of goods or service |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Software revenue (non-medical) |  | — | ​ | 40,907 | ​ | — | ​ | 40,907 | ​ | — | ​ | 40,907
Software revenue (medical) |  | 37,299 | ​ | — | ​ | — | ​ | 37,299 | ​ | — | ​ | 37,299
Medical devices and services |  | 96,941 | ​ | — | ​ | — | ​ | 96,941 | ​ | — | ​ | 96,941
Manufacturing |  | — | ​ | — | ​ | 92,486 | ​ | 92,486 | ​ | — | ​ | 92,486
Total revenue from contracts with customers |  | 134,239 | ​ | 40,907 | ​ | 92,486 | ​ | 267,633 | ​ | — | ​ | 267,633
Timing of revenue recognition |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Goods/Services transferred at a point in time |  | 101,354 | ​ | 7,358 | ​ | 87,460 | ​ | 196,172 | ​ | — | ​ | 196,172
Goods/Services transferred over time |  | 32,885 | ​ | 33,549 | ​ | 5,026 | ​ | 71,460 | ​ | — | ​ | 71,460
Total revenue from contracts with customers |  | 134,239 | ​ | 40,907 | ​ | 92,486 | ​ | 267,633 | ​ | — | ​ | 267,633
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the year ended December 31, 2024
​ | ​ ​ ​ | Materialise | ​ ​ ​ | Materialise | ​ ​ ​ | Materialise | ​ ​ ​ | Total | ​ ​ ​ | ​ | ​ ​ ​ | ​
in 000€ | ​ | Medical | ​ | Software | ​ | Manufacturing | ​ | segments | ​ | Unallocated | ​ | Consolidated
Geographical markets |  | ​ |  | ​ |  | ​ |  | ​ |  | ​ |  | ​
United States of America (USA) |  | 65,288 | ​ | 16,286 | ​ | 27,010 | ​ | 108,584 | ​ | — | ​ | 108,584
Americas other than USA |  | 5,678 | ​ | 601 | ​ | 237 | ​ | 6,516 | ​ | — | ​ | 6,516
Europe (without Belgium) & Africa |  | 37,591 | ​ | 16,884 | ​ | 72,549 | ​ | 127,024 | ​ | — | ​ | 127,024
Belgium |  | 1,448 | ​ | 153 | ​ | 4,963 | ​ | 6,564 | ​ | — | ​ | 6,564
Asia Pacific |  | 6,353 | ​ | 9,975 | ​ | 1,749 | ​ | 18,077 | ​ | — | ​ | 18,077
Total revenue from contracts with customers |  | 116,358 | ​ | 43,899 | ​ | 106,508 | ​ | 266,765 | ​ | — | ​ | 266,765
Type of goods or service |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Software revenue (non-medical) |  | — | ​ | 43,899 | ​ | — | ​ | 43,899 | ​ | — | ​ | 43,899
Software revenue (medical) |  | 33,756 | ​ | — | ​ | — | ​ | 33,756 | ​ | — | ​ | 33,756
Medical devices and services |  | 82,602 | ​ | — | ​ | — | ​ | 82,602 | ​ | — | ​ | 82,602
Manufacturing |  | — | ​ | — | ​ | 106,508 | ​ | 106,508 | ​ | — | ​ | 106,508
Total revenue from contracts with customers |  | 116,358 | ​ | 43,899 | ​ | 106,508 | ​ | 266,765 | ​ | — | ​ | 266,765
Timing of revenue recognition |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Goods/Services transferred at a point in time |  | 86,436 | ​ | 11,599 | ​ | 101,876 | ​ | 199,911 | ​ | — | ​ | 199,911
Goods/Services transferred over time |  | 29,922 | ​ | 32,300 | ​ | 4,632 | ​ | 66,854 | ​ | — | ​ | 66,854
Total revenue from contracts with customers |  | 116,358 | ​ | 43,899 | ​ | 106,508 | ​ | 266,765 | ​ | — | ​ | 266,765
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ ​ | For the year ended December 31, 2023
​ | ​ | Materialise | ​ | Materialise | ​ | Materialise | ​ | Total | ​ | ​ | ​ | ​
in 000€ | ​ ​ ​ | Medical | ​ ​ ​ | Software | ​ ​ ​ | Manufacturing | ​ ​ ​ | segments | ​ ​ ​ | Unallocated | ​ ​ ​ | Consolidated
Geographical markets |  | ​ |  | ​ |  | ​ |  | ​ |  | ​ |  | ​
United States of America (USA) |  | 53,748 | ​ | 15,451 | ​ | 21,151 | ​ | 90,350 | ​ | — | ​ | 90,350
Americas other than USA |  | 5,673 | ​ | 488 | ​ | 888 | ​ | 7,049 | ​ | — | ​ | 7,049
Europe (without Belgium) & Africa |  | 34,082 | ​ | 17,708 | ​ | 78,686 | ​ | 130,476 | ​ | — | ​ | 130,476
Belgium |  | 1,155 | ​ | 130 | ​ | 6,980 | ​ | 8,265 | ​ | — | ​ | 8,265
Asia Pacific |  | 6,718 | ​ | 10,665 | ​ | 2,605 | ​ | 19,988 | ​ | — | ​ | 19,988
Total revenue from contracts with customers |  | 101,376 | ​ | 44,442 | ​ | 110,310 | ​ | 256,127 | ​ | — | ​ | 256,127
Type of goods or service |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Software revenue (non-medical) |  | — | ​ | 44,442 | ​ | — | ​ | 44,442 | ​ | — | ​ | 44,442
Software revenue (medical) |  | 31,700 | ​ | — | ​ | — | ​ | 31,700 | ​ | — | ​ | 31,700
Medical devices and services |  | 69,676 | ​ | — | ​ | — | ​ | 69,676 | ​ | — | ​ | 69,676
Manufacturing |  | — | ​ | — | ​ | 110,310 | ​ | 110,310 | ​ | — | ​ | 110,310
Total revenue from contracts with customers |  | 101,376 | ​ | 44,442 | ​ | 110,310 | ​ | 256,127 | ​ | — | ​ | 256,127
Timing of revenue recognition |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Goods/Services transferred at a point in time |  | 73,750 | ​ | 14,844 | ​ | 105,205 | ​ | 193,799 | ​ | — | ​ | 193,799
Goods/Services transferred over time |  | 27,626 | ​ | 29,598 | ​ | 5,105 | ​ | 62,329 | ​ | — | ​ | 62,329
Total revenue from contracts with customers |  | 101,376 | ​ | 44,442 | ​ | 110,310 | ​ | 256,127 | ​ | — | ​ | 256,127
​ The revenue per type of good or service including the previous years is as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ ​ | For the year ended December 31
in 000€ | ​ ​ ​ | 2025 | ​ ​ ​ | 2024 | ​ ​ ​ | 2023
Software revenue (non-medical) |  | 40,907 |  | 43,899 |  | 44,442
Software revenue (medical) |  | 37,299 |  | 33,756 |  | 31,700
Medical devices and services |  | 96,941 |  | 82,602 |  | 69,676
Manufacturing |  | 92,486 |  | 106,508 |  | 110,310
Total |  | 267,633 |  | 266,765 |  | 256,127
​ 22.1.2 Contract balances The following table provides information about receivables, contracts in progress (contract assets) and deferred income (contract liabilities) from contracts with customers. ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ ​ | As of December 31,
in 000€ | ​ ​ ​ | 2025 | ​ ​ ​ | 2024 | ​ ​ ​ | 2023
Trade receivables, included in ‘trade and other receivables’ |  | 55,906 |  | 53,718 |  | 53,505
Contract assets / contracts in progress |  | — |  | 590 |  | 637
Contract liabilities / deferred income / advances received on contracts |  | 52,208 |  | 51,792 |  | 50,390
​ We refer to Note 18 for a detail of the deferred income. Note 18 includes a split of the deferred income in current and non-current. Non-current deferred income, representing mainly maintenance contracts with terms more than one year and certain contracts with up-front fees which are allocated to performance obligations that will be satisfied over more than one year, may be recognized as revenue between one to three years. Total revenue recognized during 2025 that was included in the contract liability at the beginning of the year amounts to K€45,998. The relation between the timing of satisfaction of the performance obligations and the timing of billing resulting in contract assets and liabilities is as follows:
| ● | Maintenance services: maintenance services are typically billed at the beginning of the maintenance period resulting in deferred income that is recognized on a straightline basis over the maintenance period.
| ● | Software licenses: certain software licenses may have been billed prior to the delivery of the software key or time-based software licenses may have been billed up-front resulting in a deferred income balance.
| ● | Certain agreements in the medical segment include up-front fees such as step-in fees or milestone payments which are billed at inception of the contract but which are allocated to performance obligations which are satisfied at a later time in the contract term or which have not been recognized considering the revenue constraint (i.e. may have to be credited when customer achieves certain volume targets). In addition, certain contracts include prepaid fees for volume “Plan Only” purchases for which the purchased services are only delivered during a one year period. Those fees result in deferred income which are recognized as revenue when services/products are delivered and revenue is not constrainted.
| ● | Certain development services are satisfied while the services can only billed at certain pre-defined points in time or when the services are fully satisfied resulting in contracts in progress / contract assets.
​ 22.2 Cost of sales Cost of sales includes the following selected information: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ ​ | For the year ended December 31
in 000€ | ​ | 2025 | ​ ​ ​ | 2024 | ​ ​ ​ | 2023
Purchase of goods and services |  | (49,207) |  | (52,576) |  | (53,747)
Amortization and depreciation |  | (11,890) |  | (11,607) |  | (11,298)
Payroll expenses |  | (53,719) |  | (51,705) |  | (46,678)
Work in Progress |  | 133 |  | (52) |  | 727
Total |  | (114,684) |  | (115,940) |  | (110,996)
​ 22.3 Research and development expenses Research and development expenses include the following selected information: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ ​ | For the year ended December 31
in 000€ | ​ | 2025 | ​ ​ ​ | 2024 | ​ ​ ​ | 2023
Purchase of goods and services |  | (6,392) |  | (6,026) |  | (4,759)
Amortization and depreciation |  | (1,414) |  | (1,696) |  | (1,459)
Payroll expenses |  | (38,283) |  | (36,678) |  | (31,900)
Other |  | — |  | — |  | 20
Total |  | (46,089) |  | (44,400) |  | (38,098)
​ 22.4 Sales and marketing expenses Sales and marketing expenses include the following selected information: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ ​ | For the year ended December 31
in 000€ | ​ ​ ​ | 2025 | ​ ​ ​ | 2024 | ​ ​ ​ | 2023
Purchase of goods and services |  | (10,810) |  | (10,949) |  | (10,437)
Amortization and depreciation |  | (2,162) |  | (2,319) |  | (2,285)
Payroll expenses |  | (48,620) |  | (48,328) |  | (45,100)
Other |  | — |  | (24) |  | —
Total |  | (61,591) |  | (61,620) |  | (57,822)
​ 22.5 General and administrative expenses General and administrative expenses include the following selected information: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ ​ | For the year ended December 31
in 000€ | ​ ​ ​ | 2025 | ​ ​ ​ | 2024 | ​ ​ ​ | 2023
Purchase of goods and services |  | (8,781) |  | (7,154) |  | (7,211)
Amortization and depreciation |  | (3,236) |  | (2,747) |  | (2,361)
Payroll expenses |  | (28,123) |  | (29,696) |  | (27,496)
Other |  | 17 |  | — |  | —
Total |  | (40,122) |  | (39,597) |  | (37,068)
​ 22.6 Net other operating income/ (expense) The net other operating income can be detailed as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ ​ | For the year ended December 31
in 000€ | ​ | 2025 | ​ ​ ​ | 2024 | ​ ​ ​ | 2023
Government grants |  | 5,282 |  | 4,913 |  | 4,853
Amortization intangibles purchase price allocation(1) |  | (3,078) |  | (3,326) |  | (4,012)
Allowance for doubtful debtors |  | (418) |  | (95) |  | (448)
Tax credits |  | 913 |  | 1,246 |  | 1,360
Arbitration settlement |  | — |  | — |  | (5,189)
Impairment of intangible assets (Note 6) and PP&E (Note 7) |  | — |  | — |  | (3,054)
Impairment of goodwill (Note 5) |  | — |  | — |  | (1,175)
Other | ​ | 1,090 | ​ | 1,485 | ​ | 1,141
Total |  | 3,789 |  | 4,223 |  | (6,524)
(1) | The Amortization intangibles purchase price allocation relates to the amortization of intangibles assets recognized in purchase price allocations from the acquisitions of Materialise Motion, Engimplan, ACTech, E-Prototypy, OrthoView, Cenat, Link3D, Identify3D and FEops NV. As of December 31, 2025, the remaining amortization period for the acquired customer relationships is 2.1 years for Materialise Motion and 11.0 years for ACTech. The customer relationships acquired in Engimplan, E-Prototypy, OrthoView and Cenat are fully amortized. As of December 31, 2025, the remaining amortization period for the acquired technology and contracts is 1.8 years for Materialise Motion and 5.6 years for FEops NV. The amortization of these assets does not directly relate to specific functional areas such as cost of sales or research and development.
The Company has received government grants from the Belgian federal and regional governments and from the European Community in the forms of grants linked to certain of its research and development programs and reduced payroll taxes. The income from capital government grants recorded in other operating income related to our German production facility amounted to K€319 for the year ended December 31, 2025 (2024: K€0; 2023: K€0). In May 2023, the Belgian Center for Arbitration and Mediation issued a decision in the arbitration proceedings filed by ZimmerBiomet against Materialise, pursuant to which we were ordered to pay an amount of € 5.2 million, including interests, to ZimmerBiomet. 22.7 Payroll expenses The following table shows the breakdown of payroll expenses for 2025, 2024 and 2023: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ ​ | For the year ended December 31
in 000€ | ​ | 2025 | ​ ​ ​ | 2024 | ​ ​ ​ | 2023
Short-term employee benefits |  | (131,533) |  | (127,328) |  | (117,443)
Social security expenses |  | (24,288) |  | (22,370) |  | (19,430)
Expenses defined contribution plans |  | (1,371) |  | (1,743) |  | (1,586)
Other employee expenses |  | (11,558) |  | (14,965) |  | (12,715)
Total |  | (168,750) |  | (166,406) |  | (151,174)
Total registered employees at the end of the period |  | 2,556 |  | 2,514 |  | 2,437
​ 22.8 Financial expenses Financial expenses includes the following selected information: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ ​ | For the year ended December 31
in 000€ | ​ | 2025 | ​ ​ ​ | 2024 | ​ ​ ​ | 2023
Interest expense |  | (1,712) |  | (1,299) |  | (1,751)
Foreign exchange losses |  | (3,539) |  | (1,310) |  | (1,770)
Other financial expenses |  | (365) |  | (360) |  | (344)
Total |  | (5,616) |  | (2,969) |  | (3,865)
​ 22.9 Financial income Financial income includes the following selected information: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ ​ | For the year ended December 31
in 000€ | ​ | 2025 | ​ ​ ​ | 2024 | ​ ​ ​ | 2023
Interest income |  | 2,838 |  | 4,252 |  | 4,450
Foreign exchange gains |  | 1,109 |  | 3,416 |  | 563
Other finance income |  | 20 |  | 9 |  | 6
Total |  | 3,967 |  | 7,677 |  | 5,019
​ Interest income is primarily related to interest received on short-term deposits of surplus cash. Interest income decreased to K€2,838 mainly as a result of lower market interest rates in the year ended in December 31, 2025 compared to K€4,252 in the year ended December 31, 2024. ​ 22.10 Income taxes and deferred taxes Current income tax The following table shows the breakdown of the tax expense for 2025, 2024 and 2023: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ ​ | As of December 31,
in 000€ | ​ | 2025 | ​ ​ ​ | 2024 | ​ ​ ​ | 2023
Current income tax |  | (934) |  | (1,861) |  | (2,355)
Deferred income taxes |  | 1,363 |  | 1,128 |  | 2,277
Total income taxes for the period |  | 429 |  | (733) |  | (78)
​ The current tax expense is equal to the amount of income tax owed to the tax authorities for the year, under the applicable tax laws and rates in effect in the various countries. Deferred tax Deferred tax is presented in the statement of financial position under non-current assets and non-current liabilities, as applicable. The following table shows the breakdown of the deferred tax assets, deferred tax liabilities and the deferred tax expense for 2025, 2024 and 2023: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ ​ | Asset/(liability) | ​ ​ ​ | Income/(expense)
in 000€ | ​ ​ ​ | 2025 | ​ ​ ​ | 2024 | ​ ​ ​ | 2023 | ​ ​ ​ | 2025 | ​ ​ ​ | 2024 | ​ ​ ​ | 2023
Tax losses, patent and innovation income deduction, and other tax credits |  | 3,225 |  | 3,263 |  | 3,199 |  | — |  | — |  | —
Amortization development assets and other intangible assets |  | 2,016 |  | 1,357 |  | 400 |  | — |  | — |  | —
Depreciation property, plant & equipment |  | 384 |  | 338 |  | 224 |  | — |  | — |  | —
Leases |  | 129 |  | 48 |  | 53 |  | — |  | — |  | —
Non deductible expenses | ​ | 163 | ​ | — | ​ | — | ​ | — | ​ | — | ​ | —
Other items |  | 198 |  | 314 |  | 343 |  | — |  | — |  | —
Total deferred tax assets |  | 6,115 |  | 5,320 |  | 4,220 |  | 1,282 |  | 1,877 |  | 3,623
Property, plant & equipment |  | (980) |  | (541) |  | (569) |  | — |  | — |  | —
Intangible assets |  | (3,637) |  | (3,847) |  | (3,664) |  | — |  | — |  | —
Deferred income | ​ | — | ​ | (425) | ​ | (743) | ​ | — | ​ | — | ​ | —
Investment grants |  | (11) |  | (159) |  | (172) |  | — |  | — |  | —
Prepaid expenses | ​ | (102) | ​ | — | ​ | — | ​ | — | ​ | — | ​ | —
Other items |  | (74) |  | (27) |  | — |  | — |  | — |  | —
Total deferred tax liabilities |  | (4,804) |  | (5,000) |  | (5,148) |  | 81 |  | (749) |  | (1,345)
Netting |  | 2,144 |  | 1,798 |  | 1,422 |  | — |  | — |  | —
Total deferred tax assets, net |  | 3,971 |  | 3,523 |  | 2,797 |  | — |  | — |  | —
Total deferred tax liabilities, net |  | (2,660) |  | (3,202) |  | (3,725) |  | — |  | — |  | —
Total deferred tax income (expense) |  | — |  | — |  | — |  | 1,363 |  | 1,128 |  | 2,277
​ The Group has unused tax losses carried forward and Innovation Income Deduction of K€144,465 for 2025 (2024: K€119,042; 2023: K€91,753) of which K€70,402 for 2025 (2024: K€55,669; 2023: K€46,533) relating to Materialise NV. Under the Belgian Innovation Income Deduction system, companies can deduct up to 85% of their net innovation income from the taxable basis. With respect to the tax losses carried forward and Innovation Income Deductions of Materialise NV, we recognized a deferred tax asset of € 1.3 million at December 31, 2025 for Materialise NV (2024: €0.0 million, 2023: € 0.1 million). We recognized a deferred tax asset of € 0.5 million for Materialise USA (2024: € 1.2 million, 2023: €1.0 million) and a deferred tax asset of € 1.0 million for ACTech (2024: € 0.0 million; 2023: € 0.0 million). The deferred tax liability of K€4,804 as at December 31, 2025 mainly relates to the intangibles that have been recognized in connection with business combinations (mainly ACTech). Relationship between Tax Expense and Accounting Profit ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ ​ | For the year ended December 31
in 000€ | ​ | 2025 | ​ ​ ​ | 2024 | ​ ​ ​ | 2023
Profit (loss) before taxes |  | 7,287 |  | 14,139 |  | 6,772
Income tax at statutory rate of 25% |  | (1,822) |  | (3,535) |  | (1,693)
Effect of different local tax rate |  | 159 |  | (294) |  | (416)
Tax adjustments to the previous period |  | 313 |  | 125 |  | (63)
Non-deductible expenses |  | (330) |  | (301) |  | (324)
Research and development tax credits |  | 220 |  | 517 |  | 203
Innovation income deduction |  | 2,984 |  | 3,325 |  | 2,560
Non recognition of deferred tax asset |  | (2,969) |  | (1,292) |  | (1,815)
Recognition of previously unrecognized tax losses |  | 1,407 |  | 221 |  | 1,186
Non-taxable income |  | 877 |  | 574 |  | 450
Use of previous years’ tax losses and tax credits (or deductible temporary differences) for which no deferred tax assets were recognized |  | — |  | 462 |  | —
Taxes on other basis |  | (409) |  | (348) |  | (232)
Other |  | (1) |  | (187) |  | 66
Income tax benefit (expense) as reported in the consolidated income statement |  | 429 |  | (733) |  | (78)
​

X
- References No definition available. + Details
Name: | mtls_IncomeAndExpensesAbstract
Namespace Prefix: | mtls_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | mtls_disclosureIncomeAndExpensesTextBlock
Namespace Prefix: | mtls_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration